Inclusion Criteria:  PATIENT ELIGIBILITY CRITERIA  Patients must have current diagnosis of chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) Patients' medical records must be available to the registering institution  Eligible patients must have been prescribed drug-based anticancer therapy, whether administered orally or by infusion, within the prior 12 months. Specifically, eligible patients are those who:  Are presently being treated with infused or orally-administered anticancer therapy, OR Completed infused or orally-administered anti-cancer therapy in the past 12 months, OR Were prescribed infused or orally-administered anticancer therapy within the prior 12 months yet chose to forego treatment Not currently enrolled in a clinical trial in which drug is supplied by the study Patients with psychiatric illness or other mental impairment that would preclude their ability to give informed consent or to respond to the telephone survey are not eligible Patients must be able to read and comprehend English or Spanish  SITE ELIGIBILITY CRITERIA  Intent to complete the Practice Survey Access to patient medical records: Registering institution must have access to patient medical records, either on site or via request from other institutions, if recruiting patients at a site (as medical abstraction is required for collecting study data). Sites seeking to enroll Spanish- speaking patients must have Spanish speaking staff on site or through the use of a translation service to be able to conduct the informed consent discussion in Spanish.  PHYSICIAN ELIGIBILITY CRTERIA  The physician currently treats patients with chronic lymphocytic leukemia (CLL) and/or multiple myeloma (MM). The physician is a treating physician at a site which has opened this protocol (LCCC 2063) and/or a site which opened the Alliance protocol (A231602CD; ClinicalTrials.gov Identifier: NCT03870633). Eligible physicians do not need to have their own patients enrolled onto this protocol.